NCT01159587View on ClinicalTrials.gov

Prophylaxis Versus On-demand Therapy Through Economic Report

CompletedOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hemophilia A
Interventions
DRUG

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly

DRUG

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

On-demand treatment with product given only for bleeding episodes

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY